Literature DB >> 16627243

[Endometrial cancer by laparoscopy and vaginal approach in the obese patient].

Frédéric Caquant1, Marie Mas-Calvet, Caroline Turbelin, Anne Lesoin, Daniele Lefebvre, Fabrice Narducci, Denis Querleu, Eric Leblanc.   

Abstract

To prove feasibility of laparoscopic and vaginal surgical approach in obese patients with endometrial cancer, 81 patients were included retrospectively in 2 Cancer Centres : 41 obese and 40 non obese. We performed hysterectomy with oophorectomy and pelvic lymphadenectomy by laparoscopic and vaginal approach. Operative time was higher for obese patients vs non obese (150 vs 121 minutes, p = 0.01) but pelvic nodes (16.3 vs 16.2), postoperative stay (3.8 [2-8] vs 3.6 days [2-7]), complications and disease-free survival (93 % vs 83 %) were similar. Matching 41 obese patients treated by laparoscopy with 29 obese patients with endometrial cancer treated by laparotomy, hospital stay was shorter in the laparoscopic group (3.8 [2-8] vs 7.4 days [5-10] p < 0.001) and pelvic nodes (16.3 [3-50] vs 11.5 [2-34]), operative time (149.9 [80-300] vs 167.9 minutes [60-390]) and disease-free survival (93 vs 80 %) were similar. One patient treated by laparotomy never received intended radiotherapy because of a delay greater than 3 months caused by cutaneous necrosis. For obese patients with stage I endometrial adenocarcinoma, laparoscopic approach should be first choice because of similar operative complications and pelvic nodes, shorter hospital stay and less abdominal wall morbidity associated with lower risk to delay adjuvant radiotherapy.

Entities:  

Mesh:

Year:  2006        PMID: 16627243

Source DB:  PubMed          Journal:  Bull Cancer        ISSN: 0007-4551            Impact factor:   1.276


  1 in total

1.  Laparoscopy versus laparotomy for the management of endometrial carcinoma in morbidly obese patients: a prospective study.

Authors:  Özgür Bige; Ahmet Demir; Bahadır Saatli; Meral Koyuncuoğlu; Uğur Saygılı
Journal:  J Turk Ger Gynecol Assoc       Date:  2015-07-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.